Identity
What is Semax?
A synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro.

Research reference · Cognition & Sleep
Semax is a synthetic heptapeptide derived from ACTH(4-10). It is registered as a medicine in Russia and studied mainly in stroke and nervous-system models.
Published by Elevated Pharma ·
Identity
A synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro.
Research context
Animal studies cover stroke, spinal cord injury and Alzheimer’s models; Russian clinical studies examine stroke recovery but are mostly not placebo-controlled.
Evidence boundary
The cited research does not establish an FDA-approved use or a human safety conclusion.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 24, 2026 (recommended). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.
Read the sourceFDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).
Read the sourceKey studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 210 PubMed records for Semax · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.